Open Orphan PLC (AIM:ORPH, FRA:CRO) (AIM:ORPH, FRA:CRO) Cathal Friel joins Proactive London after announcing their hVIVO arm has won an £8.1mln contract with an unnamed ‘major global pharmaceutical company’ to test an antiviral product using its asthma human challenge study model.
It will use as the challenge agent the human rhinovirus, the most prevalent cause of the common cold, which can exacerbate the symptoms of asthma, a condition suffered by 5.4mln people in the UK.
Friel also discusses their Malaria challenge study model which recently launched and the possibility of malaria challenge study contracts.